Geode Capital Management LLC Grows Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

Geode Capital Management LLC increased its stake in MaxCyte, Inc. (NASDAQ:MXCT) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,474,632 shares of the company’s stock after buying an additional 47,960 shares during the period. Geode Capital Management LLC owned about 2.35% of MaxCyte worth $9,628,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Mudita Advisors LLP grew its holdings in MaxCyte by 5.6% during the 3rd quarter. Mudita Advisors LLP now owns 3,153,441 shares of the company’s stock worth $12,267,000 after acquiring an additional 167,101 shares in the last quarter. State Street Corp lifted its position in shares of MaxCyte by 5.1% during the third quarter. State Street Corp now owns 2,269,135 shares of the company’s stock worth $8,827,000 after purchasing an additional 111,066 shares during the last quarter. River Global Investors LLP lifted its position in shares of MaxCyte by 4.7% during the third quarter. River Global Investors LLP now owns 2,062,562 shares of the company’s stock worth $8,034,000 after purchasing an additional 93,340 shares during the last quarter. ArrowMark Colorado Holdings LLC grew its stake in MaxCyte by 13.8% in the third quarter. ArrowMark Colorado Holdings LLC now owns 1,394,947 shares of the company’s stock worth $5,426,000 after purchasing an additional 169,250 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC increased its holdings in MaxCyte by 0.7% in the third quarter. Chevy Chase Trust Holdings LLC now owns 1,332,048 shares of the company’s stock valued at $5,182,000 after buying an additional 9,488 shares during the last quarter. Institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Up 1.2 %

Shares of NASDAQ MXCT opened at $4.16 on Thursday. The stock’s 50 day moving average price is $3.79 and its two-hundred day moving average price is $4.01. MaxCyte, Inc. has a 52-week low of $3.16 and a 52-week high of $5.55. The stock has a market capitalization of $439.67 million, a P/E ratio of -12.23 and a beta of 1.37.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02. The business had revenue of $8.16 million for the quarter, compared to analyst estimates of $7.50 million. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. During the same period in the prior year, the company posted ($0.11) EPS. On average, analysts anticipate that MaxCyte, Inc. will post -0.42 EPS for the current year.

MaxCyte Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.